Stockreport

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

ZIOPHARM Oncology Inc  (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com
PDF – Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-t [Read more]